File(s) under permanent embargo
Concomitant botanical medicine use among patients participating in commercial prostate cancer trials
Design: Retrospective study.
Setting: Regulatory repository of commercial clinical trial data.
Interventions: Anti-cancer therapy.
Main outcome measures: Botanical and medication use data were pooled across six international commercial randomized trials for metastatic prostate cancer with detailed information on medication and indications. Botanical products were considered to have potential for drug interaction if they led to a change in drug exposure in human trials. Potential for interaction was ascertained by PubMed review. Descriptive statistics were used for analysis.
Results: Of 7,318 enrolled patients, 700 (10%) reported botanical use at any time and 653 (9%) reported use of botanical products while on trial. Nearly half of botanical product types were not classified by plant (43%). The highest proportion of botanical use was among patients in Asian countries (32%), followed by patients in North America (13%). Eighty-six different types of botanical products were used; of these, nineteen had a patient-reported anti-cancer indication.
Conclusions: Botanical medicine use among patients with prostate cancer in commercial trials is moderate, although it varies by region. Practitioners should be aware of the use of botanical interventions in a clinical trial context.
History
Publication title
Complementary Therapies in MedicineVolume
54Pagination
1-8ISSN
0965-2299Department/School
Menzies Institute for Medical ResearchPublisher
Churchill LivingstonePlace of publication
Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh, Scotland, Midlothian, Eh1 3AfRights statement
© 2020 Elsevier Ltd. All rights reserved.Repository Status
- Restricted